MarginsXMarginsX
Home › Markets › Health Care › EWTX

Edgewise Therapeutics Inc. (EWTX)

EWTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$43.68
-4.90% on the day
Market cap
$4.8B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerEWTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001710072
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
4.1 months
$68.7M cash at September 30, 2026
Share count, 1 year
+3.4%
2025-10-31 to 2026-10-31 · +72.5% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$19.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$68.7M cash; operating cash flow -$50.5M a quarter.Report 2026-09-30
Shares outstanding109,482,763 (2026-10-31); 105,868,434 a year earlier; 63,461,608 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Denver, Colorado, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $199K, sold $19.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed$1.2B-$78.3M$68.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$57.3M-$42.5M$72.3MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$49.0M-$42.5M$33.2MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed-$50.2M-$38.6M$61.1MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$40.7M-$34.8M$46.0MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$36.1M-$32.6M$43.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$40.8M-$37.9M$49.9MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
Not filed-$39.7M-$27.0M$41.7MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-04-02
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-04
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 425 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month+26.6%
3 months+6.4%
Year to date+85.1%
1 year+124.9%
From 52-week high-5.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
LQDALiquidia Corporation$56.37-1.81%$5.1B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
ERASErasca Inc.$15.11-3.51%$5.3B
MANEVeradermics Incorporated$128.05-1.24%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier